Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-350270
Filing Date
2026-08-14
Accepted
2026-08-14 06:34:23
Documents
74
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rntx-20260630.htm   iXBRL 10-Q 2217576
2 EX-3.5 rntx-ex3_5.htm EX-3.5 8381
3 EX-31.1 rntx-ex31_1.htm EX-31.1 17526
4 EX-31.2 rntx-ex31_2.htm EX-31.2 17762
5 EX-32.1 rntx-ex32_1.htm EX-32.1 8724
6 EX-32.2 rntx-ex32_2.htm EX-32.2 8715
  Complete submission text file 0001193125-26-350270.txt   10085413

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rntx-20260630.xsd EX-101.SCH 1463987
77 EXTRACTED XBRL INSTANCE DOCUMENT rntx-20260630_htm.xml XML 1718955
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38130 | Film No.: 261275929
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)